Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer

被引：0
|
作者：
Jichao He
Ronan P. McLaughlin
Vera van der Noord
John A. Foekens
John W. M. Martens
Gerard van Westen
Yinghui Zhang
Bob van de Water
机构：
[1] Leiden University,Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research
[2] Erasmus Medical Centre,Department of Medical Oncology and Cancer Genomic Netherlands, Erasmus MC Cancer Institute
来源：
Breast Cancer Research and Treatment | 2019年 / 178卷
关键词：
Multi-kinase inhibitor; mTOR-targeted therapy; Drug resistance; Triple-negative breast cancer (TNBC); Polypharmacology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：263 / 274
页数：11
相关论文
共 50 条
  • [1] Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
    He, Jichao
    McLaughlin, Ronan P.
    van der Noord, Vera
    Foekens, John A.
    Martens, John W. M.
    van Westen, Gerard
    Zhang, Yinghui
    van de Water, Bob
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (02) : 263 - 274
  • [2] Multitargeted kinase inhibition (AEE788) alleviates mTOR inhibitor drug resistance in triple-negative breast cancer
    He, Jichao
    McLaughlin, Ronan P.
    van der Noord, Vera
    van Westen, Gerard
    Zhang, Yinghui
    van de Water, Bob
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Role of mTOR inhibition in triple-negative breast cancer
    Massihnia, Daniela
    Bronte, Giuseppe
    Castiglia, Marta
    Barraco, Nadia
    Cangemi, Antonina
    Perez, Alessandro
    Fanale, Daniele
    Pantuso, Gianni
    Vieni, Salvatore
    Calo, Valentina
    Rolfo, Christian D.
    Bazan, Viviana
    Russo, Antonio
    CANCER RESEARCH, 2016, 76
  • [4] Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer
    Diamond, Jennifer R.
    Orth, James D.
    Ionkina, Anastasia
    Dailey, Kyrie
    Pitts, Todd M.
    Capasso, Anna
    Marcus, Joshua M.
    Burke, Russell T.
    Davis, Sarah L.
    Kim, Jiyhe
    Tan, Aik-Choon
    Eckhardt, Sue G.
    Tentler, John J.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [5] Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer
    Haga, Yuya
    Higashisaka, Kazuma
    Yang, Lili
    Sekine, Naoki
    Lin, Ying
    Tsujino, Hirofumi
    Nagano, Kazuya
    Tsutsumi, Yasuo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 533 (04) : 672 - 678
  • [6] PLK1 inhibition overcomes PARP inhibitor resistance in triple-negative breast cancer
    Siraj, Abdul K.
    Poyil, Pratheesh Kumar
    Padmaja, Divya
    Parvathareddy, Sandeep Kumar
    Alobaisi, Khadija
    Begum, Rafia
    Almalik, Osama
    Al-Dayel, Fouad
    Al-Kuraya, Khawla S.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Targeted Therapies in Triple-Negative Breast Cancer
    Marme, Frederik
    Schneeweiss, Andreas
    BREAST CARE, 2015, 10 (03) : 159 - 166
  • [8] Targeted Treatment of Triple-Negative Breast Cancer
    Young, Joanna A.
    Tan, Antoinette R.
    CANCER JOURNAL, 2021, 27 (01): : 50 - 58
  • [9] A Phase II Preoperative Study of Dasatinib, a Multi-Targeted Tyrosine Kinase Inhibitor, in Locally Advanced "Triple Negative" Breast Cancer Patients.
    Rimawi, M. F.
    Rodriguez, A. A.
    Yang, W. T.
    Gonzalez-Angulo, A. M.
    Nangia, J. R.
    Wang, T.
    Speers, C.
    Mills, G.
    Hilsenbeck, S. G.
    Brown, P. H.
    Chang, J. C.
    CANCER RESEARCH, 2011, 71
  • [10] Targeted Therapies for Triple-Negative Breast Cancer
    Tomas G. Lyons
    Current Treatment Options in Oncology, 2019, 20
12345